Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements.”View the 10-Q filed Nov 12, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
AIM ImmunoTech Inc. announced an Ampligen pancreatic cancer presentation and expects DURIPANC Phase 2 topline results in Q1 2027, followed by overall survival, progression-free survival, quality of life and immune-response analyses in Q3 2027.
At AIM ImmunoTech Inc.’s virtual annual meeting on November 17, 2026, stockholders will elect five directors, ratify BDO USA, P.C. for the fiscal year ending December 31, 2026 and approve executive compensation; the Board recommends FOR all three.
AIM ImmunoTech Inc. is focusing Ampligen development on late-stage pancreatic cancer; patients have enrolled in the DURIPANC Phase 2 study, and the PPD clinical research business of Thermo Fisher Scientific will design an anticipated Phase 3 trial.
